Candidates must be researchers or makers with an irrepressible desire to turn a disruptive idea into an innovative product. This product is expected to add significant value to the lives of patients and consumers or to the success of commercial users.

Only applications from the field of synthetic biology, including but not only DNA synthesis, gene editing, gene therapy, mRNA vaccines and therapeutics, enzyme engineering, synthetic cells, xeno-nucleic acids, and CAR T-cells, will be considered and only applicants with legal capacity based and active in the European Union, the United Kingdom, Switzerland and Israël are invited to apply.

The scope of the competition is open to biomedical, environmental and industrial indications, but the project must always be aimed at bringing a better solution to a clear and proven unmet need. Diversity is encouraged and all qualified applicants from any nationality, social, ethnic, racial and gender categories are welcome to submit their proposal.